The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin. RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target trial enrolled adults (≥18 years) with type 2 diabetes who were either insulin naïve and receiving oral antidiabetic drugs (OADs) (HbA1c = 7–11%) or previously on basal insulin ± OAD(s) (HbA1c = 7–10%). Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8–40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230). The primary outcome was noninferiority of IDeg OD Flex to IGlar OD in HbA1c reduction after 26 weeks. RESULTS: After 26 weeks, IDeg OD Flex, IDeg OD, and IGlar OD improved HbA1c by 1.28, 1.07, and 1.26% points, respectively (estimated treatment difference [IDeg OD Flex − IGlar OD]: 0.04% points [–0.12 to 0.20], confirming noninferiority). No statistically significant differences in overall or nocturnal hypoglycemia were found between IDeg OD Flex and IGlar OD. Comparable glycemic control and rates of hypoglycemia were seen with IDeg OD Flex and IDeg OD. Adverse event profiles were similar across groups. CONCLUSIONS: The use of extreme dosing intervals of 8–40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“two treat-to-target, randomised studies where extreme dosing intervals of 8–40 h were used in subjects with T1DM and T2DM over a treatment duration of 26–52 weeks [49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“the concentration of IDeg-specific antibodies and antibodies cross-reacting with IDeg and human insulin was found to be low in studies in patients with T1DM [48, 49] or T2DM [50, 53], indicating that the risk of immunogenicity with IDeg is minimal.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“the studies showed that there was no apparent association between the development of cross-reacting antibodies and hypoglycaemia, HbA1c or insulin dose [48, 49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
(2009) · JIBL · doi:10.1515/jibl.2009.12 · Cited by 768
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Self-citationMire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Research works printed but not linked: 3
- International Diabetes Federation Diabetes Atlas. 5th ed. Brussels, Belgium, International Diabetes Federation, 2011
- Heise T Hövelmann U Nosek L Bøttcher SG Granhall C Haahr H Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract). Diabetologia 2011; 54: S425
- Kurtzhals P Heise T Strauss HM Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract). Diabetologia 2011; 54: S426
Cited by
Items 101–200 of 226
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Bohn, B., Zimmermann, A., Wagner, C., Merger, S. R., Dunstheimer, D., Kopp, F., Gollisch, K. S. C., Zindel, V., & Holl, R. W. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.031 · Cited by 15
Johnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 16
Woo, V. C., Berard, L., & Roscoe, R. S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00915-w · Cited by 17
Frias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Lajara, R., Cengiz, E., & Tanenberg, R. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1298522 · Cited by 15
Kadowaki, T., Jinnouchi, H., Kaku, K., Hersløv, M. L., Hyllested-Winge, J. L., & Nakamura, S. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12502 · Cited by 15
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
Kerlan, V., Thuillier, P., & Alavi, Z. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54953 · Cited by 15
Suzuki, J., Yamakawa, T., Oba, M., Nagakura, J., Shigematsu, E., Tamura, H., Takahashi, K., Okamoto, Y., Sakamoto, R., Shinoda, M., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0309 · Cited by 13
Okada, M., Okada, M., Nishigami, J., Yamaaki, N., Furukawa, K., Ohyama, K., Shimada, T., & Sai, Y. (2015) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-015-0027-2 · Cited by 12
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
Frier, B. M., Ratzki‐Leewing, A. A., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13732 · Cited by 12
Harris, K., & Nealy, K. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017726348 · Cited by 14
Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice
Davis, C. S., Fleming, J. W., Malinowski, S. S., Brown, M. A., & Fleming, L. W. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000076 · Cited by 17
Long-Acting Basal Insulins: A Review of the More Recently Approved Agents
Aragon, K. G., Elmaoued, A. A., Pham, N.-Y. T., Conklin, J. R., & Ray, G. M. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000266 · Cited by 12
New insulin preparations: A primer for the clinician
Meneghini, L. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83.s1.05 · Cited by 13
Self-citationNew Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins
George, C. M., Byun, A., & Howard-Thompson, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.01.049 · Cited by 13
Fulcher, G., Mehta, R., Fita, E. G., Ekelund, M., & Bain, S. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0531-0 · Cited by 12
Self-citationNew Insulins and Insulin Therapy
Danne, T., & Bolinder, J. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.1505 · Cited by 11
Yang, Y., Long, C., Li, T., & Chen, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.890090 · Cited by 11
Yamada, K., Nakayama, H., Sato, S., Tajiri, Y., Kaku, H., Tokubuchi, I., Kato, T., Soejima, E., & Ohki, T. (2014) · Diabetology International · doi:10.1007/s13340-013-0154-7 · Cited by 10
Lalic, N. M., Russel-Szymczyk, M., Culic, M., Tikkanen, C. K., & Chubb, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0426-0 · Cited by 13
BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion
Bajaj, S., Das, A. K., Kalra, S., Sahay, R. K., Saboo, B., Das, S., Shunmugavelu, M., Jacob, J. J., Priya, G., Khandelwal, D., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0629-z · Cited by 13
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0511-4 · Cited by 12
Vargas‐Uricoechea, H., & Pablo, F. J. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.001 · Cited by 11
Advances in Care for Insulin-Requiring Patients Without Closed Loop
Lal, R., Buckingham, B. A., & Maahs, D. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0084 · Cited by 10
Hompesch, M., Patel, D. K., LaSalle, J. R., & Bolli, G. B. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1568136 · Cited by 10
Insulin Past, Present, and Future: 100 Years from Leonard Thompson
Brink, S. J. (2022) · Diabetology · doi:10.3390/diabetology3010010 · Cited by 15
A comprehensive approach to type 2 diabetes mellitus – A recommendation document
Reyes‐García, R., Moreno-Pérez, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Martín, J. E.-S., et al. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.10.013 · Cited by 20
Rosenstock, J., BAJAJ, H. S., Lingvay, I., & Heller, S. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003930 · Cited by 12
Insulin degludec is a new ultra-long-acting insulin analogue
Dedov, I. I., & Shestakova, M. V. (2014) · Diabetes Mellitus · doi:10.14341/dm2014291-104 · Cited by 8
Self-citationGhosal, S., Sinha, B., & Gangopadhyay, K. K. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.013 · Cited by 9
Concentrated Insulins: A Review and Recommendations.
Gonzalvo, J. D., Patel, D. K., & Olin, J. L. (2017) · Europe PMC (PubMed Central) · Cited by 8
Ikushima, I., Kaku, K., Hirao, K., Bardtrum, L., & Haahr, H. L. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12399 · Cited by 9
Cohen, C. M., Thorsted, B. L., Wolden, M. L., Chodick, G., & Karasik, A. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0297-9 · Cited by 9
A primer on concentrated insulins: what an internist should know
Barnosky, A., Shah, L., Meah, F. A., Emanuele, N., Emanuele, M. A., & Mazhari, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1159909 · Cited by 8
Vora, J. P., Seufert, J., Solberg, H., Kinduryte, O., Johansen, T., & Hollander, P. A. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12621 · Cited by 8
Self-citationThe potential effect of ultra-long insulin degludec on glycemic variability
Rodacki, M., Carvalho, R. M., & Zajdenverg, L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.003 · Cited by 8
Dehghani, M., Sadeghi, M., Barzkar, F., Maghsoomi, Z., Janani, L., Motevalian, S. A., Loke, Y. K., Ismail‐Beigi, F., Baradaran, H. R., & Khamseh, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1286827 · Cited by 9
Brunton, S., Kruger, D. F., & Funnell, M. M. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.1.34 · Cited by 8
Nishimura, A., Harashima, S., Fukushige, H., Wang, Y., Liu, Y., Hosoda, K., & Inagaki, N. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0238-7 · Cited by 9
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
Evans, M., Morgan, A. R., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01061-7 · Cited by 7
Self-citationFadini, G. P., Buzzetti, R., Nicolucci, A., Larosa, M., Rossi, M. C., Cucinotta, D., On behalf of the RESTORE-2 Study Group, Gabellieri, E., Alberto, M., Pagotto, U., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01925-9 · Cited by 7
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
Kaku, K., Wolden, M. L., Hyllested-Winge, J. L., & Nørtoft, E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0225-z · Cited by 6
Lualdi, C., Silverii, G. A., Dicembrini, I., Pala, L., Monami, M., & Mannucci, E. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0920-2 · Cited by 6
Modern basal insulin analogs: An incomplete story
Singh, A. K., & Gangopadhyay, K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.140239 · Cited by 6
Mori, H., Taniguchi, S., Tamaki, Y., Tamaki, M., Akehi, Y., Kuroda, A., & Matsuhisa, M. (2024) · Nutrients · doi:10.3390/nu16020268 · Cited by 8
Ghosal, S., Sinha, B., & Gangopadhyay, K. K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s63878 · Cited by 6
Kaku, K., & Eid, M. A. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12348 · Cited by 6
Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice
Evans, M., & McEwan, P. C. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.10 · Cited by 5
The clinical impact of hypoglycemia in hospitalized patients
Borzì, V., & Fontanella, A. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.2015.549 · Cited by 6
Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1 and Type 2 Diabetes Mellitus
Berard, L., & Macneill, G. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.02.019 · Cited by 6
Weatherall, J., Bloudek, L. M., & Buchs, S. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1251893 · Cited by 6
Agmon, O., Sigawi, T., & Ilan, Y. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100262 · Cited by 6
Should we Fear Insulin Therapy in the Treatment of Type 2 Diabetes?
Haslam, D. B. (2014) · The Open Obesity Journal · doi:10.2174/1876823701406010070 · Cited by 4
Advances in Basal Insulin Therapy
Goldman, J. D., & White, J. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516667128 · Cited by 4
The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
Strain, W. D., Morgan, A. R., & Evans, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01162-3 · Cited by 4
Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_1 · Cited by 6
Kesavadev, J., Murthy, L. S., Chaudhury, T., Yalamanchi, S. R., Giri, J., Gupta, S., Phatak, S., Modi, K. D., Chatterjee, S., Manjunath, A., et al. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100184 · Cited by 4
Inpatient hyperglycemia management: the opportunities of a new basal insulin
Simioni, N. (2016) · Italian Journal of Medicine · doi:10.4081/itjm.2016.681 · Cited by 4
New Insulins and Insulin Therapy
Bolinder, J., & Danne, T. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1505 · Cited by 4
Shestakova, M. V., Antciferov, M. V., Mayorov, A. Y., Ruyatkina, L. A., Суплотова, Л. А., Dogadin, S. A., Lebedev, N. B., & Alekseeva, Y. G. (2015) · Diabetes Mellitus · doi:10.14341/dm7694 · Cited by 5
Self-citationHigher concentration insulins: an overview of clinical considerations
Reid, T., Schafer, F., & Brusko, C. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1325311 · Cited by 3
Sethi, B. K., Unnikrishnan, A., Ayyar, V. S., Jabbar, P. K., Ganguly, K. K., Bhandari, S., Rastogi, A., Mukherjee, R., Sundaram, V., & Asirvatham, A. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01284-2 · Cited by 3
Ponomareva, E., Schmerold, L. M., Srinivas, S. S. S., Preblick, R., Park, S., Wilson, L., & Revel, A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277058 · Cited by 3
Dyakov, I. N., & Zyryanov, S. K. (2021) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2020-5-4-14 · Cited by 3
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1029455 · Cited by 3
Røder, M. E. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1043270 · Cited by 3
Muñoz‐Torres, M. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.02.010 · Cited by 4
Chawla, M. S., Chawla, P., Saboo, B., Chawla, R., Gangopadhyay, K. K., Kalra, S., Aravind, S. R., Sinha, B., Shah, T. U., Kesavadev, J., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102587 · Cited by 2
de Adana, M. S. R., Domínguez, M., Morillas, V., Colomo, N., Mora, M. R. V., Guerrero, M., García‐Escobar, E., Carreira, M., Romero‐Zerbo, S., Linares, F., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110238 · Cited by 3
Muñoz‐Torres, M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.03.012 · Cited by 3
Learning About New Therapies: Phase 3 Clinical Studies—And Beyond
Riddle, M. C. (2013) · Diabetes Care · doi:10.2337/dc13-1019 · Cited by 2
Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes
Khunti, K., Cos, X., & Rutten, G. E. H. M. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.09.003 · Cited by 2
Characteristics and practicalities of a new basal insulin
Stockley, S. (2014) · British Journal of Nursing · doi:10.12968/bjon.2014.23.1.16 · Cited by 2
Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus
Keating, G. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0073-5 · Cited by 2
Thurston, M. M., Galdo, J. A., & Bourg, C. A. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.1.20 · Cited by 2
Insulin Therapy in Type 2 Diabetes
Moghissi, E. S. (2013) · US Endocrinology · doi:10.17925/use.2013.09.01.6 · Cited by 2
Meadowcraft, L., Mospan, G. A., Morrisette, T., Smart, K., & Janis, M. (2016) · The Nurse Practitioner · doi:10.1097/01.npr.0000508167.22111.34 · Cited by 2
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Rendell, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s132581 · Cited by 3
Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.
Chung, J. W., Hartzler, M. L., Smith, A. A., Hatton, J., & Kelley, K. W. (2018) · Europe PMC (PubMed Central) · Cited by 5
Lüdemann, J., Milek, K., Wilhelm, B., Segner, A., & Jaeckel, E. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-3481-0 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Vargas‐Uricoechea, H., & Frías, J. P. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.014 · Cited by 2
McCarthy, O. M., Bain, S. C., & Deere, R. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.63 · Cited by 2
Self-citationIn-Hospital Management of Hyperglycemia: The Role of Insulin Degludec
WANGNOO, S. K., Baruah, M. P., Lodha, S., Sanyal, D., Goyal, R., Sooragonda, B. G., Chandrasekaran, S., & Kumar, G. V. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01707-w · Cited by 2
Mohebbi, A., Kjøller, N.-K., Johansen, A. R., Bengtsson, H. L., Jensen, M. L., Stallknecht, B. M., & Mørup, M. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11253142 · Cited by 1
Farahani, P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.913980 · Cited by 1
Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.
Mithal, A., Kumar, A., Jain, S. M., & Kumar, H. (2014) · PubMed · Cited by 1
Degludec: a long-duration insulin
Alexanderson-Rosas, E. G., Llamas-Moreno, J. F., Castro-Martínez, M. G., Frenk-Barón, P., Romo-Pérez, O. A., & Mena-Madrazo, J. A. (2015) · Medicina Interna de México · Cited by 2
Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1216974 · Cited by 1
Expanded Basal Insulin Options for Type 2 Diabetes Mellitus
Olin, J. L., & Harris, K. B. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.07.011 · Cited by 2
Paediatric type 1 diabetes 2018: Clinical and research insights
Zborovski, S., & Mahmud, F. H. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxx214 · Cited by 2
Management of Hypoglycemia in Patients with Type 2 Diabetes
Unger, J. (2018) · Archives of Diabetes & Obesity · doi:10.32474/ado.2018.01.000116 · Cited by 1
New Pharmacologic Agents for Diabetes Treatment.
Malham, S. B., & Herrick, C. (2016) · Europe PMC (PubMed Central) · Cited by 1
Efficacy, safety and clinical use of newer basal insulins analogs
Neto, A. M., & Ferrari, M. T. M. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00178 · Cited by 2
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
Dyakov, I. N., & Zyryanov, S. K. (2021) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2021-1-4-15 · Cited by 1
Puglisi, S. C., Mackiewicz, A. L., Ardeshir, A., Garzel, L. M., & Christe, K. L. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-20-000075 · Cited by 1
▼Insulin degludec for diabetes mellitus
(2013) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2013.7.0190 · Cited by 1
[Therapeutic compliance and flexibility in the use of basal insulins].
Gil, J. E. C., Litwak, L., Fuente, G. V., & Faingold, M. C. (2014) · PubMed · Cited by 5
Ampudia‐Blasco, F. J. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.10.001 · Cited by 2
Metadata
- Authors
- Meneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., & on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators
- Affiliations
- University of Miami (US)
- Hull York Medical School (GB)
- Churchill Hospital (GB)
- Hadassah Medical Center (IL)
- Ochsner Health System (US)
- Endocrinology Research Center (RU)
- Singleton Hospital (GB)
- Novo Nordisk (Denmark) (DK)
- Oslo University Hospital (NO)
- Corresponding author
- Meneghini, Luigi
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-03-14
- Volume
- 36
- Issue
- 4
- Pages
- 858-864
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3609505
- OpenAlex
- W2146026006
- Semantic Scholar
- 26c9a57c740ae859eaa21ee58bc49f8d9da1fc6d
- Cited by
- 226
- References
- 26
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 10 · 2020: 11 · 2019: 20 · 2018: 31 · 2017: 21 · 2016: 29 · 2015: 27 · 2014: 34 · 2013: 22
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, insulin glargine, basal insulin analogues, type 2 diabetes, injection timing, glycemic control, HbA1c, hypoglycemia, non-inferiority
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.